Ginkgo Bioworks Stock News

Cathie Wood's focus on disruptive technologies could be a winning strategy over the long term. Ginkgo Bioworks and Recursion Pharmaceuticals are two of her more intriguing holdings in the biotech indu

One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.

Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.

These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.

Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential gian

Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most fro

The cell programming upstart is partnering with behemoths like Pfizer and Alphabet. The business remains unproven, incurring heavy losses over the past four quarters.

Finding a great small-cap stock to buy isn't always easy. We know that, over the long run, small-cap stocks as a whole outperform large-cap cousins.

Ginkgo Bioworks' Q3 results were relatively poor due to the difficult macro environment and the winding down of its COVID testing business. While Ginkgo's Cell Engineering business has enormous potent

Ginkgo Bioworks is successfully scaling its customer base. It's also making some progress towards profitability.

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.

Ginkgo Bioworks Holdings Inc. (NYSE:DNA ) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Dire

No investor likes a big earnings miss. While the biotech beat on the top line for its third quarter, that bottom-line whiff was glaring.

Ark Invest bought shares of Toast, Ginkgo Bioworks, and Robinhood Markets on Wednesday. The three stocks fell as much as 14% on Wednesday after disappointing quarterly results.

No-brainer buys offer you a compelling future growth story for a great price. The idea is to make a small investment today and hold on for the long term when your patience could pay off.